The integration of artificial intelligence (AI) and machine learning (ML) in clinical trials is poised to significantly improve participant recruitment and retention. Researchers are investigating how these technologies can streamline processes and enhance operational functions within clinical research. Notably, AI tools are capable of identifying optimal trial sites, which could lead to a potential increase in enrollment rates by as much as 20%.
Moreover, employing AI and ML can shorten the timeline for bringing innovative therapies to market, with development periods reduced by an average of six months per asset. A 12-month reduction in clinical development could enhance a sponsor’s portfolio by over $400 million in net present value, according to the WCG’s 2026 Trends & Insights report. This transformation is supported by predictive analytics that optimize site selection, reducing costly mid-study adjustments.
Additionally, machine learning facilitates proactive trial monitoring, allowing study teams to identify risks earlier and allocate resources more effectively. These advancements not only improve the speed and quality of trial execution but also enhance the overall efficiency of clinical development processes.